Avenue Therapeutics Stock Quote ATXI - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

2.72

Bid

2.70

Ask

3.10

Volume

133,744

2.60 Day's Range 3.0598

2.60 52 Week Range 87.00

Market Cap

2.559M

Previous Close

2.87

Open

2.84

Last Trade

2.8

Last Trade Time

Financial Volume

$ 377,786

VWAP

2.8247

Average Volume (3m)

74,335

Shares Outstanding

940,986

Dividend Yield

PE Ratio

-0.24

Earnings Per Share (EPS)

-11.03

Revenue

Net Profit

-10.38M

Avenue Therapeutics Inc is a specialty pharmaceutical company that develops and markets pharmaceutical products for the acute care setting. It focuses on developing its product candidate, an intravenous (IV) formulation of tramadol HCI (IV Tramadol), for post-operative acute pain. Avenue Therapeutics Inc is a specialty pharmaceutical company that develops and markets pharmaceutical products for the acute care setting. It focuses on developing its product candidate, an intravenous (IV) formulation of tramadol HCI (IV Tramadol), for post-operative acute pain.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.avenuetx.com

Headquarters

Dover, Delaware, USA

Founded

1970

Avenue Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ATXI. The last closing price for Avenue Therapeutics was $2.87. Over the last year, Avenue Therapeutics shares have traded in a share price range of $ 2.60 to $ 87.00.

Avenue Therapeutics currently has 940,986 shares outstanding. The market capitalization of Avenue Therapeutics is $2.70 million. Avenue Therapeutics has a price to earnings ratio (PE ratio) of -0.24.

Form S-8 - Securities to be offered to employees in employee benefit plans

Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

Form 8-K - Current report

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.9099	-25.0668062481	3.6299	3.9313	2.6	217554	3.08180163	CS
4	-0.86	-24.0223463687	3.58	3.9313	2.6	81674	3.20248242	CS
12	-2.1	-43.5684647303	4.82	5.97	2.6	74335	3.76985995	CS
26	-7.7875	-74.1137282893	10.5075	15	2.6	945171	10.38382556	CS
52	-79.78	-96.703030303	82.5	87	2.6	2009862	17.57388287	CS
156	-2191.03	-99.876011396	2193.75	2238.75	2.6	1800750	350.75693456	CS
260	-6578.53	-99.9586704653	6581.25	14130	2.6	1143367	718.29979249	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.55M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.51M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	258.51k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.05M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.68M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.89M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	714.54k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.01M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	404.94M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.51M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.16M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.42M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.64M